Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679412 | 1.00 | PTPRB (1.00) | PTPRB | |
| SCHEMBL679413 | 1.00 | PTPRB (1.00) | PTPRB | |
| SCHEMBL12944458 | 0.93 | PTPRB (0.87) | PTPRB | |
| SCHEMBL16060586 | 0.93 | PTPRB (0.87) | PTPRB | |
| SCHEMBL18687623 | 0.92 | PTPRB (0.85) | PTPRB | |
| SCHEMBL683388 | 0.91 | PTPRB (1.00) | PTPRB | |
| SCHEMBL468324 | 0.91 | PTPRB (1.00) | PTPRB | |
| SCHEMBL679547 | 0.91 | PTPRB (1.00) | PTPRB | |
| SCHEMBL679548 | 0.91 | PTPRB (1.00) | PTPRB | |
| SCHEMBL679088 | 0.89 | PTPRB (1.00) | PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022133232-A1 | METHODS FOR MANUFACTURE OF SMALL MOLECULE ACTIVATORS OF TIE-2 | EyePoint Pharmaceuticals, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021236985-A1 | METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH ACTIVATORS OF TIE-2 | Aerpio Pharmaceuticals, Inc. (US) | 2021-11-25 | — | — | WO | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-7622593-B2 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.